Corcept’s Relacorilant Improves Overall Survival in Platinum-Resistant Ovarian Cancer

Corcept Therapeutics’ stock rose 14% after its selective cortisol modulator, relacorilant, achieved the overall survival (OS) goal in the Phase III ROSELLA trial for platinum-resistant ovarian cancer. The study enrolled 381 patients, showing that relacorilant plus nab-paclitaxel reduced the risk of death by 35% compared with nab-paclitaxel alone. Median OS improved from 11.9 months to 16.0 months, a 4.1-month gain.

It was noted that the combination could become a new standard of care, citing the survival benefit, oral administration, and favorable tolerability. Relacorilant previously demonstrated a 30% reduction in disease progression risk in the trial’s progression-free survival endpoint. Adverse events were comparable between treatment arms.

Corcept is investigating relacorilant in other solid tumors, including endometrial, cervical, pancreatic, and prostate cancers. Full ROSELLA results will be presented at an upcoming medical conference.

27-01-2026